Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE: TAA-T for High Risk Hematopoietic Malignancies
NCT02203903Phase 1Recruiting
- Sponsor
- Catherine Bollard
- Start
- Apr 2015
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Catherine Bollard. Primary endpoints: Safety of investigational product (TAA-T) at 45 days and Event-free survival at 12 months. Started Apr 2015; status: recruiting.
02
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02203903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02203903.